This information is intended for use by health professionals

1. Name of the medicinal product

Levomepromazine Maleate 50mg Tablets.

2. Qualitative and quantitative composition

Each tablet contains 50mg of levomepromazine maleate.

Excipient with known effect:

Lactose (as lactose monohydrate) 142.50 mg per tablet.

For the full list of excipients, see section 6.1.

3. Pharmaceutical form


White to off white round shaped tablet with break line on one side and 'L2' debossing on another side.

The tablet can be divided into equal halves.

4. Clinical particulars
4.1 Therapeutic indications

Levomepromazine tablets is a neuroleptic with indications in psychiatry and general medicine, particularly in terminal illness. Clinically it is more sedative and more potent than chlorpromazine in the management of psychotic conditions and in the relief of severe chronic pain.


As an alternative to chlorpromazine in schizophrenia especially when it is desirable to reduce psychomotor activity.

General medicine – Terminal illness

Adjunct therapy in the relief of pain and the accompanying distress.

4.2 Posology and method of administration


Dosage varies with the condition under treatment and the individual response of the patient.

1. Terminal illness

The dosage is 25mg to 50mg every 4 to 8 hours.


No specific dosage recommendations.

2. Psychiatric conditions


Ambulant patients: initially the total daily oral dose should not exceed 25mg to 50mg usually divided into 3 doses; a larger portion of the dosage may be taken at bedtime to minimise diurnal sedation. The dosage is then gradually increased to the most effective level compatible with sedation and other side effects.

Bed patients: initially the total daily oral dosage may be 100mg to 200mg, usually divided into 3 doses, gradually increased to 1g daily if necessary.

When the patient is stable attempts should be made to reduce the dosage to an adequate maintenance level.


Children are very susceptible to the hypotensive and soporific effects of levomepromazine. It is advised that a total daily oral dosage of 37.5mg should not be exceeded. The average effective daily intake for a ten year old is 12.5mg to 25mg.

Elderly patients

It is not advised to give levomepromazine to ambulant patients over 50 years of age unless the risk of a hypotensive reaction has been assessed.

Method of administration

For oral use only.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Safety in pregnancy has not been established.

There are no absolute contraindications to the use of Levomepromazine in terminal care.

4.4 Special warnings and precautions for use

The drug should be avoided, or used with caution, in patients with liver dysfunction or cardiac disease.

The hypotensive effects of levomepromazine should be taken into account when it is administered to patients with cardiac disease and the elderly or debilitated. Patients receiving large initial doses should be kept in bed.

As with other neuroleptics, cases of QT interval prolongation have been reported with levomepromazine very rarely. Consequently, and if the clinical situation permits, absence of the following risk factors for onset of this type of arrhythmia should be verified prior to administration:

• Bradycardia or 2nd or 3rd degree heart block.

• Metabolic abnormalities such as hypokalaemia, hypocalcaemia or hypomagnesaemia.

• Starvation or alcohol abuse.

• A history of QT interval prolongation, ventricular arrhythmias or Torsades de Pointes.

• A family history of QT interval prolongation.

• Concomitant neuroleptics

• Ongoing treatment with another drug(s) liable to induce marked bradycardia, electrolyte imbalance, slowed intracardiac conduction or prolonged QT interval.

Prior to initiation of treatment with levomepromazine, it may be appropriate to consider an ECG with measurement of serum calcium, magnesium and potassium levels. Periodic serum electrolyte levels should be monitored and corrected if necessary, especially during long-term chronic usage. An ECG may be appropriate to assess the QT interval whenever dose escalation is proposed and when the maximum therapeutic dose is reached.


In randomized clinical trials versus placebo performed in a population of elderly patients with dementia and treated with certain atypical antipsychotic drugs, a 3-fold increase of the risk of cerebrovascular events has been observed. The mechanism for this increased risk is not known. An increased risk cannot be excluded for other antipsychotics or other patient populations. Levomepromazine should be used with caution in patients with risk factors for stroke.

Increased Mortality in Elderly people with Dementia:

Data from two large observational studies showed that elderly people with dementia who are treated with conventional (Typical) antipsychotics are at a small increased risk of death compared with those who are not treated.

There are insufficient data to give a firm estimate of the precise magnitude of the risk and the cause of the increased risk is not known.

Levomepromazine is not licensed for the treatment of dementia-related behavioural disturbances.

Venous thromboembolism:

Cases of venous thromboembolism (VTE) have been reported with antipsychotic drugs. Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with levomepromazine and preventive measures undertaken.


Hyperglycaemia or intolerance to glucose has been reported in patients treated with levomepromazine.

Patients with an established diagnosis of diabetes mellitus or with risk factors for the development of diabetes who are started on levomepromazine, should get appropriate glycaemic monitoring during treatment (see Section 4.8).


Levomepromazine may lower epileptic threshold (see section 4.8) and should be used with caution in epileptic patients.


Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

4.5 Interaction with other medicinal products and other forms of interaction

Combinations requiring precaution:

Cytochrome P450 2D6 Metabolism: There is a possible pharmacokinetic interaction between inhibitors of CYP2D6, such as phenothiazines and CYP2D6 substrates (mainly nortriptyline).

Levomepromazine and its non-hydroxylated metabolites are reported to be potent inhibitors of cytochrome P450 2D6 (CYP2D6). Co-administration of levomepromazine and drugs primarily metabolised by the CYP2D6 enzyme system may result in increased plasma concentrations of these drugs. Monitor patients for dose-dependent adverse reactions associated with CYP2D6 substrates such as amitriptyline/amitriptylinoxide.

There is an increased risk of arrhythmias when neuroleptics are used with drugs that prolong the QT interval such as certain class 1A and III antiarrhythmics (such as quinidine, disopyramide, procainamide, amiodarone, sotalol and dofetilide), certain antimicrobials (such as sparfloxacin, moxifloxacin and erythromycin IV), tricyclic antidepressants (e.g. amitriptyline), tetracyclic antidepressants (e.g. maprotiline), other neuroleptics (e.g. phenothiazines, pimozide and sertindole), antihistamines (e.g. terfenadine), cisapride, bretylium and antimalarials (e.g. quinine and mefloquine).

The anticholinergic effect of neuroleptics may be enhanced by other anticholinergic drugs.

Avoid concomitant neuroleptics and any other drugs that may cause electrolyte imbalance. Diuretics, in particular those causing hypokalemia, should be avoided but, if necessary, potassium-sparing diuretics are preferred.

Simultaneous administration of desferrioxamine and prochlorperazine has been observed to induce a transient metabolic encephalopathy, characterised by loss of consciousness for 48 to 72 hours. It is possible that this may occur with levomepromazine since it shares many of the pharmacological activities of prochlorperazine. Adrenaline (epinephrine) must not be used in patients overdosed with neuroleptics. Alcohol should be avoided.

4.6 Fertility, pregnancy and lactation


Safety in pregnancy has not been established.

Neonates exposed to antipsychotics (including levomepromazine) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborns should be monitored carefully.

Animal studies are insufficient with respect to reproductive toxicity. In humans, the teratogenic risk of levomepromazine has not been evaluated. Different prospective epidemiological studies conducted with other phenothiazines have yielded contradictory results regarding teratogenic risk. Levomepromazine is not recommended during pregnancy and in women of childbearing potential not using contraception.


Levomepromazine is excreted in breast milk in low amounts in human milk. A risk to the suckling child cannot be excluded.

A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from levomepromazine therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.


There are no fertility data in animals.

In humans, because of the interaction with dopamine receptors, levomepromazine may cause hyperprolactinaemia which can be associated with impaired fertility in women. Some data suggest that levomepromazine treatment is associated with impaired fertility in men.

4.7 Effects on ability to drive and use machines

Levomepromazine can cause drowsiness, disorientation, confusion or excessive hypotension, which may affect the patient's ability to drive or operate machinery.

4.8 Undesirable effects

Adverse effects have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100; <1/10); uncommon (≥1/1,000;<1/100); rare (≥1/10,000;<1/1,000); very rare (<1/10,000); frequency not known (cannot be estimated from the available data).

System organ class

Very common



(≥1/100 to <1/10)


(≥1/1,000 to <1/100)


(≥1/10,000 to <1/1,000)

Not known (cannot be estimated from available data)

Blood and lymphatic system disorders


Raised ESR

Cardiac disorders

QT prolongation

Ventricular arrhythmias such as ventricular tachycardia or fibrillation

Cardiac arrest

Cardiac rhythm disturbances

Sudden death/sudden cardiac death (see Section 4.4)

Torsades de Pointes (treatment of which should include discontinuation of levomepromazine and correction of hypoxia, electrolyte abnormalities and acid base disturbances)

Gastrointestinal disorders

Dry mouth


Ileus paralytic

Necrotizing enterocolitis (which can be fatal)

General disorders and administration site conditions


Heat stroke (in hot and humid conditions)

Hepatobiliary disorders


Hepatocellular, cholestatic and mixed liver injury

Metabolism and nutrition disorders

Glucose tolerance impaired

Hyperglycaemia (see Section 4.4).


Syndrome of inappropriate antidiuretic hormone secretion (SIADH)

Nervous system disorders


Parkinsonism (with prolonged high dosage)


Neuroleptic malignant syndrome

Confusional states, delirium

Pregnancy, puerperium and perinatal conditions

Drug withdrawal syndrome neonatal

(see section 4.6)

Reproductive system and breast disorders


Vascular disorders

Hypotension (especially in elderly patients)

Venous thromboembolism

Deep vein thrombosis

Pulmonary embolism

Skin and subcutaneous tissue disorders

Photosensitivity Reaction

Dermatitis allergic

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme at: or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

Symptoms of levomepromazine overdosage include drowsiness or loss of consciousness, hypotension, tachycardia, ECG changes, ventricular arrhythmias hypothermia and convulsions. Severe extrapyramidal dyskinesias may occur.

If the patient is seen sufficiently soon (up to 6 hours) after ingestion of a toxic dose, gastric lavage may be attempted. Pharmacological induction of emesis is unlikely to be of any use. Activated charcoal should be given. There is no specific antidote. Treatment is supportive.

Generalised vasodilatation may result in circulatory collapse; raising the patient's legs may suffice but, in severe cases, volume expansion by intravenous fluids may be needed; infusion fluids should be warmed before administration in order not to aggravate hypothermia.

Positive inotropic agents such as dopamine may be tried if fluid replacement is insufficient to correct the circulatory collapse. Peripheral vasoconstrictor agents are not generally recommended; avoid use of adrenaline (epinephrine).

Ventricular or supraventricular tachy-arrhythmias usually respond to restoration of normal body temperature and correction of circulatory or metabolic disturbances. If persistent or life-threatening, appropriate antiarrhythmic therapy may be considered. Avoid lidocaine (lignocaine) and, as far as possible, long acting anti-arrhythmic drugs.

Pronounced central nervous system depression requires airway maintenance or, in extreme circumstances, assisted respiration. Severe dystonic reactions usually respond to procyclidine (5mg to 10mg) or orphenadrine (20mg to 40mg) administered intramuscularly or intravenously. Convulsions should be treated with intravenous diazepam.

Neuroleptic malignant syndrome should be treated with cooling. Dantrolene sodium may be tried.

5. Pharmacological properties
5.1 Pharmacodynamic properties

ATC Code: NO5AA02

Pharmacotherapeutic group: Antipsychotics

The mechanisms of action of levomepromazine involve blocking of D2, αl- and α2-adrenergic, and Ml cholinergic receptors thereby exerting multiple therapeutic effects. It is utilized for the treatment of psychotic disturbances such as acute and chronic schizophrenias, senile psychoses, and manic-depressive syndromes. The antipsychotic effect of levomepromazine is mediated by blocking of central dopamine receptors, while the side effects are mediated by antagonism of peripheral α-adrenoceptors. Other common side effects such as dry mouth and urine retention are mediated by antagonism of muscarinic cholinergic receptors. Levomepromazine has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. A relationship has been demonstrated between the sedative effects of psychotropic drugs and their ability to antagonize histamine Hl receptors in mouse and rat brain, and it seems likely that the sedative effects of some neuroleptics may be related to their histamine receptor-blocking properties. Levomepromazine as an analgesic is also effective for the treatment of pain due to cancer, trigeminal neuralgia, and neurocostal neuralgia.

5.2 Pharmacokinetic properties

Maximum serum concentrations are achieved in 2 to 3 hours depending on the route of administration. On average 50% of orally administered drug reached the general circulation as unchanged levomepromazine. The apparent volume of distribution was 23 to 42 L/kg, and the biologic half-life, 15 to 30 hr.

The metabolism of levomepromazine was studied in man after oral administration. The study demonstrated glucuronides, sulfoxide and possibly non-oxidized drug in the urine and non-oxidized drug in the faeces. Cytochrome P450 isoenzymes involved in the 5-sulfoxidation and N-demethylation of the aliphatic-type phenothiazine neuroleptic levomepromazine were identified in human liver. CYP3A4 is the main isoform responsible for levomepromazine 5-sulfoxidation (72%) and N-demethylation (78%) at a therapeutic concentration of the drug (10 μM). CYP1A2 contributes to a lesser degree to levomepromazine 5-sulfoxidation (20%).

Excretion is slow, with a half-life of about 30 hours. It is eliminated via urine and faeces. The elimination of levomepromazine metabolites occurs mainly in the urine with only smaller amounts of unchanged drug or demethylated products in the faeces. An average 10% of the daily dose was eliminated in the urine as levomepromazine sulfoxide.

5.3 Preclinical safety data

No data on the mutagenicity or carcinogenicity of levomepromazine are available.

6. Pharmaceutical particulars
6.1 List of excipients

Lactose monohydrate

Pregelatinized maize starch

Povidone K-29/32

Silica, colloidal anhydrous

Magnesium stearate

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years.

6.4 Special precautions for storage

This medicinal product does not require any special temperature storage conditions. Store in the original package in order to protect from light.

6.5 Nature and contents of container

PVC/PVdC-Alu blisters containing 7, 10, 14, 20, 24, 28, 30, 56, 60, 84, 90, 100 and 112 tablets.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. Marketing authorisation holder

Morningside Healthcare Limited

Unit C, Harcourt Way

Leicester, LE19 1WP

United Kingdom

8. Marketing authorisation number(s)

PL 20117/0338

9. Date of first authorisation/renewal of the authorisation


10. Date of revision of the text